Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raftilose is a commercial brand of oligofructose, a prebiotic dietary fiber composed of short-chain fructo-oligosaccharides (FOS). It is typically extracted from chicory roots through partial enzymatic hydrolysis of inulin. As a prebiotic, Raftilose is not digested in the upper gastrointestinal tract but is fermented by beneficial bacteria in the colon, such as *Bifidobacterium* and *Lactobacillus* species. This fermentation leads to the production of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, which play crucial roles in maintaining intestinal barrier integrity and modulating immune responses. It is widely used as a functional food ingredient and has been investigated in clinical trials for its potential to improve gut health in patients with inflammatory bowel disease (IBD), obesity, and metabolic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oligofructose.